EFSA says CBD safety data “cannot currently be established”
“The effect of CBD on liver, gastrointestinal tract, endocrine system, nervous system and on psychological function needs to be clarified,” wrote EFSA’s Panel on Nutrition, Novel Foods and Food Allergens (NDA).
The Panel added: “Studies in animals show significant reproductive toxicity, and the extent to which this occurs in humans generally and in women of child-bearing age specifically needs to be assessed. Considering the significant uncertainties and data gaps, the Panel concludes that the safety of CBD as a NF cannot currently be established.”
Look to NutraIngredients for reactions to this opinion in the coming days.